PERSPECTIVES
TRAIN-OF-FOUR MONITORING AND THE PERSISTENT PROBLEM OF RESIDUAL NEUROMUSCULAR BLOCKADE

UDK: 616.8-009.1

Abdyli A1, Huti G1, Coniglione F1

1American Hospital, Tirana, Albania

 

Residual neuromuscular blockade (RNMB) continues to be a pervasive and underestimated perioperative risk. Recent observational studies report RNMB incidence ranging from approximately 33% in patients without objective monitoring to 5–16% when quantitative monitoring and appropriate reversal were used, highlighting both the prevalence and preventability of this complication (1).

References:

  1. Esteves S, Correia de Barros F, Nunes CS, et al. Incidence of postoperative residual neuromuscular blockade – A multicenter, observational study in Portugal (INSPIRE 2). Porto Biomed J. 2023;8(4):e225. doi: 10.1097/j.pbj.0000000000000225.
  2. Linn DD, Rech MA, Faine BA. Strategies to prevent awareness with paralysis following administration of neuromuscular blocking agents. Am J Health Syst Pharm. 2025;82(17):e736-e742. doi: 10.1093/ajhp/zxaf072.
  3. Murphy G, Szokol J, Avram M, et al. Postoperative Residual Neuromuscular Blockade Is Associated with Impaired Clinical Recovery. Anesthesia & Analgesia. 2013;117(1):133-141. DOI: 10.1213/ANE.0b013e3182742e75.
  4. Adembesa I, Mung’ayi V, Premji Z, et al. A randomized control trial comparing train of four ratio > 0.9 to clinical assessment of return of neuromuscular function before endotracheal extubation on critical respiratory events in adult patients undergoing elective surgery at a tertiary hospital in Nairobi. Afr Health Sci. 2018;18(3):807-816. doi: 10.4314/ahs.v18i3.40.
  5. Piersanti A, Garra R, Sbaraglia F et al. Neuromuscular monitoring and incidence of postoperative residual neuromuscular blockade: a prospective observational study. J Anesth Analg Crit Care. 2025; 5:5. https://doi.org/10.1186/s44158-025-00226-1.
  6. Rodney G, Raju P, Brull SJ. Neuromuscular block management: evidence-based principles and practice. BJA Educ. 2024;24(1):13-22. doi: 10.1016/j.bjae.2023.10.005.
  7. Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. British Journal of Anaesthesia. 2015;115(5):743–751.
  8. Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7(2):129-140. doi: 10.1016/S2213-2600(18)30294-7.
  9. Fuchs-Buder T, Romero CS, Lewald H, et al. Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2023;40(2):82-94. doi: 10.1097/EJA.0000000000001769.
  10. Cao, M., Huang, H., Tong, J. et al. Optimal dose of neostigmine antagonizing cisatracurium-induced shallow neuromuscular block in elderly patients: a randomized control study. BMC Anesthesiol. 2023; 23:269. https://doi.org/10.1186/s12871-023-02233-7.
  11. Blum FE, Locke AR, Nathan N, et al. Residual Neuromuscular Block Remains a Safety Concern for Perioperative Healthcare Professionals: A Comprehensive Review. J Clin Med. 2024;13(3):861. doi: 10.3390/jcm13030861.
  12. Fortier LP, McKeen D, Turner K, et al. The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade. Anesth Analg. 2015;121(2):366-72. doi: 10.1213/ANE.0000000000000757.
  13. Saager L, Maiese EM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J Clin Anesth. 2019; 55:33-41. doi: 10.1016/j.jclinane.2018.12.042.